(AnaSpec 創辦人 洪順五) 拓展國際 要靠政府幫忙!

美國安肽生技創辦人洪順五:先挺中小企業打國際盃 2016-12-27 〔記者黃以敬／台北報導〕新政府提出亞洲矽谷、生技醫療、綠能科技等五大創新產業要拚經濟，但在美國創業有成的新政府台灣海外發展委員會委員、美國安肽生技公司（AnaSpec Inc.）創辦人洪順五博士憂心指出，蔡政府的經濟政策只怕需花大錢投資卻走錯方向而無法有足夠效益，政府應先扶助廣大中小企業向國際行銷、拓展市場，只有企業賺到錢，才能談擴大就業、談加薪，台灣經濟才能有發展。洪順五指出，國民黨及馬英九執政期把台灣經濟帶往過度傾中的錯誤方向，讓台灣經濟付出慘痛代價，導致資本、技術、人力都外流，尤其佔台灣人力就業約八、九成的中小企業沒進步，很難與國際競爭，中小企業無法賺錢，就業無法提升、無法加薪， 產生惡性循環。

花大錢創新 難有快速效益 洪順五認為，蔡政府目前經濟政策也恐出現偏差，想靠幾個所謂明星產業要提升經濟，當然生技、綠能、國防等都應該做，但這些都是需大投資卻很難很快有效益的項目，例如生技新藥，過去幾個案例幾乎都變成炒股案，但台灣的製藥環境卻沒真正建立起來。他幾年前要回國設廠做多肽醫療試劑，卻找不到有相關經驗的人才，很遺憾。他強調，台灣應先扶植中小企業去做明星產業的周邊輔助性產業，例如試劑、醫材、製藥原料等，一來可培訓上萬有經驗與實力的人才，二來這些是可小規模投資、較快有收益的行業，幾年後才能真正建構起可大規模製藥的大環境。早年洪順五曾金援海外民運及民進黨，被列黑名單而二十年無法回台；他五年前將一手創立的生技公司賣給國際大廠，成立台灣行銷協會，要再幫助台灣的中小企業走入國際。他近日回台拜會經濟部、民進黨，積極呼籲政府要幫中小企業拓展國際市場。洪順五強調，現在對台灣政局最有影響性的議題不再是統獨，大多數民眾早已認同台灣的主體性、是天然獨，經濟反而是對蔡政府最大的影響因素，川普當選美國總統就是因經濟讓多數美國人不滿意，新政府如果經濟政策沒成效，恐怕會有「川普們」出現威脅政權；因此呼籲政府一定要先幫助中小企業向全球拓展市場，只有廣大企業能賺到錢，才能有更多就業機會、加薪，台灣經濟才能走出新路。

AnaSpec and EGT NA are subsidiaries of Eurogentec, which is part of the Kaneka Corporation.

About Eurogentec Eurogentec was founded in 1985 as a spin-off company of the University of Liège (Belgium). Its mission is to develop and deliver reliable, innovative products and services to the life science community. Eurogentec contributes to improving health and fighting disease by supplying products and services to scientists involved in life science research, molecular diagnostics, and therapeutic developments. The Liège-based company is recognised as one of the major suppliers in the field of genomics and proteomics as well as a trusted Contract Manufacturing Organisation (CMO) for the bio-production of pharmaceuticals (vaccines and medicines). In 2010, Eurogentec joined the Kaneka Corporation, a large Japanese chemical company focusing on technology and innovation. The Eurogentec Group is based in Belgium and has strategically-located subsidiaries all over the world, employing a total of 320 people.

About Kaneka Kaneka is an innovation-oriented chemical company. Traditionally the company has been active in polymers, fermentation, biotechnology and electronics, as well as other fields. Business activities now span a broad spectrum of markets ranging from plastics, EPS resins, chemicals and foodstuffs to pharmaceuticals, medical devices, electrical and electronic materials and synthetic fibers. The life science related activities are currently one of the strategically important domains for Kaneka. The company has been a pioneer among Japanese chemical companies in establishing overseas operations, beginning in 1970 with a subsidiary in Belgium. Kaneka Corporation is a company headquartered in Osaka-Japan, with subsidiaries in the United States, Belgium, Germany, Singapore, Malaysia, China, Australia, Vietnam, India, South Korea, Taiwan, Indonesia and Brazil. Kaneka employs more than 8,900 people worldwide.